U.S. Food and Drug Administration Approves BioMarin’s Roctavian^™ (Valoctocogene Roxaparvovec-Rvox), the First and Only Gene Therapy for Adults With Severe Hemophilia A

BioMarin Pharmaceutical Inc. announced that the US FDA approved ROCTAVIAN™ gene therapy for the treatment of adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.